Action Abivax - ABVX

Abivax SA (ABVX) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

120,8229

( 23,92% )

Prix Achat

120,30

Prix Vente

120,54

Volume échangé

2 730 306

93,05 Fourchette du Jour 99,06

7,41 Plage de 52 semaines 148,83

Cap du marché

9,629B

Clôture Veille

97,50

Ouverture

98,39

Dernière Transaction

200

120.8229

(formt)

Dernière heure de transaction

00:43:47

Volume financier

US$ 262 293 085

VWAP

96,0673

Volume moyen (3 m)

US$ 280 329

Actions en circulation

79 694 535

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-18,68

Bénéfice par action (BPA)

-4,52

Chiffre d'affairess (LTM)

4,92M

Bénéfice net (LTM)

-332,2M

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical devel... ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. Show more

Secteur

Healthcare

Industrie

Biotechnology & Life Sciences

Site Web

www.abivax.com

Siège social

Paris, France

Fondé

2026

Abivax SA est coté dans le secteur Healthcare de la NASDAQ avec le ticker ABVX. Le dernier cours de clôture d'Abivax était de US$97,50. Au cours de la dernière année, les actions de Abivax ont été négociées dans une fourchette de prix de US$ 7,41 à US$ 148,83.

Abivax compte actuellement 79 694 535 actions en circulation. La capitalisation boursière d'Abivax est de US$9,63 milliard. Abivax a un ratio cours/bénéfice (ratio PE) de -18.68.

Flux global

Haussier

Prime nette

3M

Calls / Puts

182.26%

Ach. / Vent.

96.25%

OTM / ITM

272.34%

Sweeps Ratio

1.14%

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical...

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX) PR...

Abivax Shares Tumble Despite Strong Ulcerative Colitis Trial Results as Safety Concerns Emerge (ABVX)

Abivax (NASDAQ:ABVX) shares fell sharply on Tuesday after investors focused on reports of rare malignancy cases in a late-stage clinical trial...

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to...

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	21.7229	21.9201816347	99.1	124.5	74.79	2792614	95.21550668	DR
4	-12.3271	-9.25805482538	133.15	133.27	69.81	3529639	95.07843486	DR
12	2.9329	2.48782763593	117.89	135.075	69.81	1788261	104.26349006	DR
26	-26.1771	-17.8075510204	147	147	69.81	1481765	110.81207464	DR
52	113.2929	1504.55378486	7.53	148.83	7.41	1490671	98.19196134	DR
156	109.2229	941.576724138	11.6	148.83	4.77	647394	85.30831264	DR
260	109.2229	941.576724138	11.6	148.83	4.77	647394	85.30831264	DR

ABVX - Frequently Asked Questions (FAQ)

What is the current Abivax SA share price?

The current share price of Abivax SA is US$ 120,8229

How many Abivax SA shares are in issue?

Abivax SA has 79 694 535 shares in issue

What is the market cap of Abivax SA?

The market capitalisation of Abivax SA is USD 9,63B

What is the 1 year trading range for Abivax SA share price?

Abivax SA has traded in the range of US$ 7,41 to US$ 148,83 during the past year

What is the PE ratio of Abivax SA?

The price to earnings ratio of Abivax SA is -18,68

What is the cash to sales ratio of Abivax SA?

The cash to sales ratio of Abivax SA is 1,37k

What is the registered address of Abivax SA?

The registered address for Abivax SA is 7-11 Boulevard Haussmann, Paris, Ile-de-France, 75009

What is the Abivax SA website address?

The website address for Abivax SA is www.abivax.com

Which industry sector does Abivax SA operate in?

Abivax SA operates in the Biotechnology & Life Sciences sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Abivax SA (ABVX)

Abivax SA (ABVX) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Abivax SA

Flux d'options Abivax (ABVX)

Flux global

Haussier

Prime nette

3M

Calls / Puts

182.26%

Ach. / Vent.

96.25%

OTM / ITM

272.34%

Sweeps Ratio

1.14%

ABVX Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)

Abivax Shares Tumble Despite Strong Ulcerative Colitis Trial Results as Safety Concerns Emerge (ABVX)

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B7 - Prospectus [Rule 424(b)(7)]

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)

Abivax Shares Tumble Despite Strong Ulcerative Colitis Trial Results as Safety Concerns Emerge (ABVX)

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

ABVX - Frequently Asked Questions (FAQ)

ABVX Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités